CRTX - Cortexyme gets dosing underway in early-stage COR588 trial

Cortexyme (CRTX +0.1%) announces that the first cohort of healthy participants have been dosed in the Phase 1 clinical trial of its new drug candidate COR588. The trial is a Phase 1 randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of oral COR588 capsules in healthy adult patients. Cortexyme is evaluating the efficacy of its lead lysine-gingipain inhibitor, atuzaginstat, in the company’s pivotal GAIN Trial evaluating the role of P. gingivalis in the progression of Alzheimer’s disease in mild to moderate patients. Top-line data from the GAIN Trial and REPAIR sub-study are expected by mid-November 2021.

For further details see:

Cortexyme gets dosing underway in early-stage COR588 trial